Indoco Remedies Future Growth
Future criteria checks 4/6
Indoco Remedies is forecast to grow earnings and revenue by 113% and 12.6% per annum respectively. EPS is expected to grow by 114.2% per annum. Return on equity is forecast to be 12.5% in 3 years.
Key information
113.0%
Earnings growth rate
114.17%
EPS growth rate
| Pharmaceuticals earnings growth | 16.0% |
| Revenue growth rate | 12.6% |
| Future return on equity | 12.47% |
| Analyst coverage | Low |
| Last updated | 11 May 2026 |
Recent future growth updates
Analysis Article • May 10
The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...Analysis Article • Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Analysis Article • Jan 24
₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Recent updates
Narrative Update • Jun 19
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.Narrative Update • Jun 04
INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.Analysis Article • May 10
The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...Narrative Update • May 09
INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Analysis Article • Sep 05
Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Analysis Article • Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Analysis Article • Jul 01
Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Analysis Article • Jan 29
Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
New Narrative • Jan 26
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.Analysis Article • Jan 24
₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Analysis Article • Oct 27
Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Analysis Article • May 24
Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Analysis Article • Jan 26
Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Analysis Article • Jan 26
Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Sep 16
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Analysis Article • May 21
Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Aug 31
Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Analysis Article • Jul 04
Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Analysis Article • Jul 02
Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Analysis Article • Jun 10
Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 23,777 | 1,257 | 1,979 | 2,914 | 4 |
| 3/31/2027 | 21,091 | 721 | 2,273 | 3,520 | 2 |
| 3/31/2026 | 18,453 | -951 | 447 | 1,922 | N/A |
| 12/31/2025 | 17,599 | -1,139 | N/A | N/A | N/A |
| 9/30/2025 | 17,251 | -1,105 | -960 | 1,408 | N/A |
| 6/30/2025 | 16,713 | -1,122 | N/A | N/A | N/A |
| 3/31/2025 | 16,649 | -737 | -2,612 | 949 | N/A |
| 12/31/2024 | 17,243 | -107 | N/A | N/A | N/A |
| 9/30/2024 | 17,732 | 321 | -3,076 | 2,220 | N/A |
| 6/30/2024 | 18,223 | 767 | N/A | N/A | N/A |
| 3/31/2024 | 18,173 | 985 | -2,706 | 1,554 | N/A |
| 12/31/2023 | 17,958 | 1,016 | N/A | N/A | N/A |
| 9/30/2023 | 17,356 | 1,134 | -911 | 1,442 | N/A |
| 6/30/2023 | 16,869 | 1,281 | N/A | N/A | N/A |
| 3/31/2023 | 16,686 | 1,423 | -284 | 1,788 | N/A |
| 12/31/2022 | 16,496 | 1,569 | N/A | N/A | N/A |
| 9/30/2022 | 16,084 | 1,617 | 85 | 1,703 | N/A |
| 6/30/2022 | 15,622 | 1,537 | N/A | N/A | N/A |
| 3/31/2022 | 15,408 | 1,548 | 485 | 1,738 | N/A |
| 12/31/2021 | 14,368 | 1,393 | N/A | N/A | N/A |
| 9/30/2021 | 14,110 | 1,317 | 257 | 1,391 | N/A |
| 6/30/2021 | 13,524 | 1,157 | N/A | N/A | N/A |
| 3/31/2021 | 12,415 | 930 | 54 | 822 | N/A |
| 12/31/2020 | 12,084 | 734 | N/A | N/A | N/A |
| 9/30/2020 | 11,654 | 571 | 387 | 931 | N/A |
| 6/30/2020 | 11,298 | 393 | N/A | N/A | N/A |
| 3/31/2020 | 11,066 | 241 | 644 | 1,228 | N/A |
| 12/31/2019 | 10,909 | 302 | N/A | N/A | N/A |
| 9/30/2019 | 10,640 | 264 | N/A | N/A | N/A |
| 6/30/2019 | 10,071 | 111 | N/A | N/A | N/A |
| 3/31/2019 | 9,684 | -29 | N/A | 1,321 | N/A |
| 3/31/2018 | 10,424 | 412 | N/A | 1,227 | N/A |
| 3/31/2017 | 10,968 | 771 | N/A | 886 | N/A |
| 3/31/2016 | 10,081 | 819 | N/A | 1,122 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INDOCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.9%).
Earnings vs Market: INDOCO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: INDOCO is expected to become profitable in the next 3 years.
Revenue vs Market: INDOCO's revenue (12.6% per year) is forecast to grow faster than the Indian market (10.9% per year).
High Growth Revenue: INDOCO's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INDOCO's Return on Equity is forecast to be low in 3 years time (12.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 19:54 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indoco Remedies Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |